Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice
Authors:
- Viking HussVHViking Huss
- Hjalmar WadströmHWHjalmar Wadström
- the ARTIS groupTGthe ARTIS group
- Gerd-Marie AhleniusGAGerd-Marie Ahlenius
- Eva BaecklundEBEva Baecklund
- Katerina ChatzidionysiouKCKaterina Chatzidionysiou
- Nils FelteliusNFNils Feltelius
- Helena Forsblad-D’eliaHFHelena Forsblad-D’elia
- Alf KastbomAKAlf Kastbom
Open Access
- 29 July 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (5) , 1810-1818
Abstract
To estimate the occurrence and relative risks of first-ever-incident non-cutaneous cancer overall and for 16 sites in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs), by time since treatment start, attained age, and duration of active treatment. This is an observational nationwide and population-based cohort study of patients with RA (n = 69 308), treated with TNF inhibitors (TNFi; adalimumab, certolizumab, etanercept, golimumab, infliximab) or other b/tsDMARDs (abatacept, rituximab, baricitinib, tofacitinib and tocilizumab) compared with RA patients not treated with b/tsDMARDs, and matched general population referents (n = 109 532), 2001–2018. The study was based on prospectively collected data from the Swedish Rheumatology Quality Register and from other registers, linked to the national Swedish Cancer Register. Incidence rates and hazard ratios were estimated via Cox regression adjusted for co-morbidities and other health characteristics. Based on 8633 incident cancers among RA patients, the overall relative risk of cancer with TNFi [hazard ratio (HR) = 1.0] was neither increased nor did it change with time since treatment start, duration of active treatment, or attained age, when compared with b/tsDMARD-naïve RA. For other b/tsDMARDs, we noted no consistent signal of increased overall risks (HRs ranged from 1.0 to 1.2), but there were statistically significant estimates above 1 for abatacept with 2–5 years of active treatment, for older age groups, and between several of the bDMARDs and urinary tract cancer. TNFis, as used long term in clinical practice against RA, are not linked to increased risks for cancer overall. For other b/tsDMARDs, and for site-specific risks, our results are generally reassuring but contain signals that call for replication.Keywords
Funding Information
- Karolinska Institute Region Stockholm
This publication has 22 references indexed in Scilit:
- Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO RegistryAnnals of the Rheumatic Diseases, 2013
- Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohortJoint Bone Spine, 2011
- Immunity, Inflammation, and CancerCell, 2010
- Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBITArthritis Research & Therapy, 2010
- Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?Arthritis & Rheumatism, 2009
- Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational studyArthritis & Rheumatism, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- Paradoxical roles of the immune system during cancer developmentNature Reviews Cancer, 2006
- Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonistsAnnals of the Rheumatic Diseases, 2005